Prognosis of Parkinson's disease: Time to stage III, IV, V and to motor fluctuations

Movement Disorders

Volumn 21, Issue 9, 2006, Pages 1384-1395

  Sato, Kenichi ^a   Hatano, Taku ^a   Yamashiro, Kazuo ^a   Kagohashi, Maki ^a   Nishioka, Kenya ^a   Izawa, Nana ^a   Mochizuki, Hideki ^a   Hattori, Nobutaka ^a   Mori, Hideo ^a   Mizuno, Yoshikuni ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hoehn Yahr stage; Mortality; Parkinson's disease; Prognosis; Treatment

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CABERGOLINE; DICHLORISOPRENALINE; LEVODOPA; PERGOLIDE; SELEGILINE; TALIPEXOLE;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONSULTATION; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE DURATION; DYSKINESIA; FEMALE; HUMAN; MAINTENANCE DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SEX DIFFERENCE;

ADULT; AGE FACTORS; AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; DISABILITY EVALUATION; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; JAPAN; LEVODOPA; MALE; MIDDLE AGED; MOBILITY LIMITATION; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PROGNOSIS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS;

EID: 33750289632     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.20993     Document Type: Article

References (48)

1. Calne DB, Snow BJ, Lee C. Criteria for diagnosing Parkinson's disease. Ann Neurol 1992;32:S125-S127.
2. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, editors. The Scientific Basis for the Treatment of Parkinson's Disease. Carnforth: Parthenon Publishing Group; 1992. p 89-112.
3. Koller WC, Hutton JT, Tolosa E, Capilldeo R, the Carbidopa/Levodopa Study Group. Immediate-release and controlled-release carbidopa/levodopa in PD. A 5-year randomized multicenter study. Neurology 1999;53:1012-1019.
4. Caraceni T, Scigliano G, Musicco M. The occurrence of motor fluctuations in parkinsonian patients treated long term with levodopa: role of early treatment and disease progression. Neurology 1991;41:380-384.
5. Parkinson's Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
6. Schrag A, Quinn N. Dyskinesias and motor fluctuations in Parkinson's disease. A community-based study. Brain 2000;123:2297-2305.
7. McColl CD, Reardon KA, Shiff M, Kempster PA. Motor response to levodopa and the evolution of motor fluctuations in the first decade of treatment of Parkinson's disease. Mov Disord 2002;17: 1227-1234.
8. Ballard PA, Tetrud JW, Langston JW. Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): seven cases. Neurology 1985;35:949-956.
9. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. An examination of male-female differences in progression and mortality of Parkinson's disease. Neurology 1990;40:763-766.
10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
11. Goetz CG, Tanner CM, Stebbins GT, Bochman AS. Risk factors for progression in Parkinson's disease. Neurology 1988;38:1841-1844.
12. Jankovic J, Kapadia AS. Functional decline in Parkinson's disease. Arch Neurol 2001;58:1611-1615.
13. Marras C, Rochon P, Lang A.E. Predicting motor decline and disability in Parkinson disease: a systematic review. Arch Neurol 2002;59:1724-1728.
14. Roos RA, Jongen JC, van der Velde EA. Clinical course of patients with idiopathic Parkinson's disease. Mov Disord 1996;11:236-242.
15. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. N Engl J Med 2000;342:1484-1491.
16. Holloway RG, Shoulson I, Fahn S, et a]. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. Arch Neurol 2004;61:1044-1053.
17. Markham CH, Diamond SG. Evidence to support early levodopa therapy in Parkinson disease. Neurology 1981:31:125-131.
18. Scigliano G, Musicco M, Soliveri P, et a]. Mortality associated with early and late levodopa therapy initiation in Parkinson's disease. Neurology 1990;40:265-269.
19. Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord 1999; 14:911-913.
20. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
21. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on progression and mortality in Parkinson's disease. Neurology 1989;39:1187-1190.
22. Hely MA, Morris JG, Reid WG, et al. Age at onset: the major determinant of outcome in Parkinson's disease. Acta Neurol Scand 1995;92:455-463.
23. Guillard A, Chastang C, Fenelon G. Long-term study of 416 cases of Parkinson disease: prognostic factors and therapeutic implication in Parkinson's disease. Rev Neurol (Paris) 1986;142:207-214.
24. Hoehn MM. Parkinson's disease: progression and mortality. Adv Neurol 1987;45:457-461.
25. Raschetti R, Spila-Alegiani S, Vanacore N, Ancona C, Meco G. Mortality in a population-based cohort of patients treated with antiparkinsonian drugs. Acta Neurol Scand 1998;97:20-26.
26. Herlofson K, Lie SA, Arsland D, Larsen JP Mortality and Parkinson disease: a community based study. Neurology 2004;62:937-942.
27. Hely MA, Morris JG, Traficante R, Reid WG, O'Sullivan DJ, Williamson PM. The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years. J Neurol Neurosurg Psychiatry 1999;67:300-307.
28. Fall PA, Saleh A, Fredrickson M, Olsson JE, Granerus AK. Survival time, mortality, and cause of death in elderly patients with Parkinson's disease: a 9-year follow-up. Mov Disord 2003;18: 1312-1316.
29. Elbaz A, Bower JH, Peterson BJ, et al. Survival study of Parkinson disease in Olmsted County, Minnesota. Arch Neurol 2003;60:91-96.
30. Hughes TA, Ross HF, Mindham RH, Spokes EG. Mortality in Parkinson's disease and its association with dementia and depression. Acta Neurol Scand 2004;110:118-123.
31. Rajput AH, Offord KP, Beard CM, Kurland LT. Epidemiology of parkinsonism: incidence, classification, and mortality. Ann Neurol 1984;16:278-282.
32. Imaizumi Y. Geographical variations in mortality from Parkinson's disease in Japan, 1977-1985. Acta Neurol Scand 1995;91: 311-316.
33. Sweet RD, McDowell FH. Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. Ann Intern Med 1975;83:456-463.
34. Wermuth L, Stenager EN, Stenager E, Boldsen J. Mortality in patients with Parkinson's disease. Acta Neurol Scand 1995;92:55-58.
35. Minami Y, Yamamoto R, Nishikouri M, Fukao A, Hisamichi S. Mortality and cancer incidence in patients with Parkinson's disease. J Neurol 2000;247:429-434.
36. Bennett DA, Beckett LA, Murray AM, et al. Prevalence of parkinsonian signs and associated mortality in a community population of older people. N EngI J Med 1996;334:71-76.
37. Ebmeier KP, Calder SA, Crawford JR, Stewart L, Besson JA, Mutch WJ. Parkinson's disease in Aberdeen: survival after 3.5 years. Acta Neurol Scand 1990;81:294-299.
38. Morens DM, Davis JW, Grandinetti A, Ross GW, Popper JS, White LR. Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men. Neurology 1996;46:1044-1050.
39. Guttman M, Slaughter PM, Theriault ME, DeBoer DP, Naylor CD. Parkinsonism in Ontario: increased mortality compared with controls in a large cohort study. Neurology 2001;57:2278-2282.
40. Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: possible clues to aetiology? J Neurol Neurosurg Psychiatry 1995;58:293-299.
41. Morgante L, Salemi G, Meneghini F, et al. Parkinson disease survival: a population-based study. Arch Neurol 2000;57:507-512.
42. Joseph C, Chassan JB, Koch ML. Levodopa in Parkinson disease: a long-term appraisal of mortality. Ann Neurol 1978;3:116-118.
43. Chen RC, Chang SF, Su CL, et al. Prevalence, incidence, and mortality of PD: a door-to-door survey in Ilan county, Taiwan. Neurology 2001;57:1679-1686.
44. Imaizumi Y. Longitudinal Gompertzian analysis of Parkinson's disease mortality in Japan, 1950-1993. Mech Ageing Dev 1995; 85:15-23.
45. Lilienfeld DE, Chan E, EhIand J, et al. Two decades of increasing mortality from Parkinson's disease among the US elderly. Arch Neurol 1990;47:731-734.
46. Berger K, Breteler MM, Helmer C, et al. Prognosis with Parkinson's disease in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54(Suppl. 5):S24-S27.
47. Riggs JE. Longitudinal Gompertzian analysis of Parkinson's disease mortality in the U.S., 1955-1986: the dramatic increase in overall mortality since 1980 is the natural consequence of deterministic mortality dynamics. Mech Ageing Dev 1990;55:221-233.
48. Nakashima K, Maeda M, Tabata M, Adachi Y, Kusumi M, Ohshiro H. Prognosis of Parkinson's disease in Japan. Tottori University' Parkinson's Disease Epidemiology (TUPDE) Study Group. Eur Neurol 1997;38(Suppl. 2):60-63.